(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.39%) $79.26
(-0.49%) $2.03
(0.15%) $2 313.10
(0.54%) $26.98
(0.45%) $966.90
(-0.06%) $0.932
(-0.17%) $10.97
(-0.12%) $0.797
(-0.03%) $91.10
5 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products...
Stats | |
---|---|
Šios dienos apimtis | 356 700 |
Vidutinė apimtis | 612 594 |
Rinkos kapitalizacija | 206.07B |
EPS | ¥0 ( 2024-02-07 ) |
Kita pelno data | ( ¥14.64 ) 2024-05-08 |
Last Dividend | ¥8.50 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 22.72 |
ATR14 | ¥0.575 (0.05%) |
Tūris Koreliacija
Nipro Corporation Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Nipro Corporation Koreliacija - Valiuta/Žaliavos
Nipro Corporation Finansinės ataskaitos
Annual | 2022 |
Pajamos: | ¥545.20B |
Bruto pelnas: | ¥163.45B (29.98 %) |
EPS: | ¥28.04 |
FY | 2022 |
Pajamos: | ¥545.20B |
Bruto pelnas: | ¥163.45B (29.98 %) |
EPS: | ¥28.04 |
FY | 2022 |
Pajamos: | ¥494.79B |
Bruto pelnas: | ¥149.27B (30.17 %) |
EPS: | ¥82.50 |
FY | 2021 |
Pajamos: | ¥455.56B |
Bruto pelnas: | ¥138.84B (30.48 %) |
EPS: | ¥87.12 |
Financial Reports:
No articles found.
Nipro Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥13.50 (N/A) |
¥0 (N/A) |
¥8.50 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥8.75 | 2001-03-27 |
Last Dividend | ¥8.50 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 45 | -- |
Total Paid Out | ¥561.75 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.13 | -- |
Div. Sustainability Score | 7.70 | |
Div.Growth Potential Score | 3.47 | |
Div. Directional Score | 5.59 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9531.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8174.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7552.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6101.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4812.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4026.T | Ex Dividend Knight | 2023-10-30 | Semi-Annually | 0 | 0.00% | |
3242.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
2267.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9042.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0177 | 1.500 | 9.65 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00921 | 1.200 | 9.69 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0455 | 1.500 | -0.605 | -0.908 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.495 | 0.800 | 7.52 | 6.02 | [1 - 3] |
quickRatioTTM | 0.717 | 0.800 | -0.486 | -0.389 | [0.8 - 2.5] |
cashRatioTTM | 0.222 | 1.500 | 9.88 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.539 | -1.500 | 1.023 | -1.534 | [0 - 0.6] |
interestCoverageTTM | 4.49 | 1.000 | 9.45 | 9.45 | [3 - 30] |
operatingCashFlowPerShareTTM | 686.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 686.29 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 2.46 | -1.500 | 0.157 | -0.236 | [0 - 2.5] |
grossProfitMarginTTM | 0.300 | 1.000 | 8.33 | 8.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0466 | 1.000 | -1.069 | -1.069 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.187 | 1.000 | -0.0728 | -0.0728 | [0.2 - 2] |
assetTurnoverTTM | 0.520 | 0.800 | 9.87 | 7.89 | [0.5 - 2] |
Total Score | 7.70 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.24 | 1.000 | 8.06 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0455 | 2.50 | -0.389 | -0.908 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 686.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.967 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 686.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -3.82 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.194 | 1.000 | 7.66 | 0 | [0.1 - 0.5] |
Total Score | 3.47 |
Nipro Corporation
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. The company's Medical Device business develops, manufactures, and sells various disposable medical products comprising renal, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, diabetic, and cell cultures products; and sells artificial organ-related products, and generic and kit products. Its Pharmaceutical business provides pharmaceutical combination products, including dual chamber bags, pre-filled syringes, and half-type kits; and contract manufacturing services for orally administered drugs, injectables, and external preparations. The company's Pharma Packaging business offers glass vials, ampoules, syringes, and cartridges; glass tubes; glass forming machinery; glass bulbs for vacuum flasks; and other parts of pharmaceutical packaging, such as rubber plugs. Its Other business provides thermostable enzymes for clinical chemistry. The company also offers business management services. Nipro Corporation serves customers in Japan, the Americas, Europe, and rest of Asia. The company was founded in 1947 and is headquartered in Osaka, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.